好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Alemtuzumab Compared with Subcutaneous High-Dose IFNB-1a in Treatment-Naive Relapsing-Remitting Multiple Sclerosis: Primary Efficacy Outcomes of CAMMS223 at 3 Years
MS and Related Diseases
(-)
006
Authors/Disclosures
Alasdair Coles, MD, PhD (University of Cambridge) Dr. Coles has nothing to disclose.
No disclosure on file
No disclosure on file